EdgeMarket › What Ra Capital Management, L.P. reported owning
What Ra Capital Management, L.P. reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
9.4BPositions
85Quarter
2026-03-31Shown below
50largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| ASND Ascendis Pharma A/S | 2.4B | 24.9% | 10.3M | 253.29 | +31.4% |
| PCVX Vaxcyte, Inc. | 666.8M | 7.1% | 11.5M | 62.62 | +100.3% |
| RYTM RHYTHM PHARMACEUTICALS, INC. | 579.8M | 6.1% | 6.7M | 110.00 | +11.4% |
| TYRA Tyra Biosciences, Inc. | 467.2M | 5.0% | 12.2M | 26.05 | +154.4% |
| SION Sionna Therapeutics, Inc. | 397.1M | 4.2% | 9.9M | 5.29 | -76.8% |
| EWTX Edgewise Therapeutics, Inc. | 328.5M | 3.5% | 10.4M | 44.18 | +219.2% |
| NAMS NewAmsterdam Pharma Co N.V. | 305.7M | 3.2% | 9.6M | 27.87 | +14.6% |
| unmapped CUSIP 670703107 | 259.6M | 2.8% | 2.5M | — | — |
| DNTH Dianthus Therapeutics, Inc. /DE/ | 219.2M | 2.3% | 2.6M | 111.10 | +374.4% |
| MLYS Mineralys Therapeutics, Inc. | 208.4M | 2.2% | 7.7M | 25.65 | +65.7% |
| SGP SpyGlass Pharma, Inc. | 207.8M | 2.2% | 8.0M | 26.51 | — |
| WVE Wave Life Sciences, Inc. | 195.6M | 2.1% | 27.0M | 5.29 | -44.0% |
| SEPN Septerna, Inc. | 168.1M | 1.8% | 7.0M | 40.00 | +260.7% |
| IRON Disc Medicine, Inc. | 156.7M | 1.7% | 2.5M | 79.81 | +35.9% |
| JANX Janux Therapeutics, Inc. | 155.5M | 1.6% | 11.2M | 17.39 | -30.1% |
| BCRX BIOCRYST PHARMACEUTICALS INC | 150.7M | 1.6% | 15.8M | 9.55 | +14.0% |
| BCAX Bicara Therapeutics Inc. | 144.3M | 1.5% | 7.3M | 23.90 | +118.1% |
| PRAX Praxis Precision Medicines, Inc. | 120.4M | 1.3% | 373.8K | 375.94 | +730.8% |
| GHRS GH Research PLC | 107.9M | 1.1% | 7.7M | 28.33 | +121.7% |
| ZLAB Zai Lab Ltd | 107.4M | 1.1% | 5.7M | 26.01 | -22.4% |
| TSHA Taysha Gene Therapies, Inc. | 105.3M | 1.1% | 23.6M | 6.09 | +112.2% |
| VOR Vor Biopharma Inc. | 96.4M | 1.0% | 5.4M | 23.36 | -46.9% |
| GERN GERON CORP | 95.0M | 1.0% | 63.8M | 1.52 | +9.4% |
| SPRY ARS Pharmaceuticals, Inc. | 87.2M | 0.9% | 10.9M | 5.50 | -62.3% |
| SRPT Sarepta Therapeutics, Inc. | 84.9M | 0.9% | 3.9M | 18.79 | -8.7% |
| SYRE Spyre Therapeutics, Inc. | 81.8M | 0.9% | 1.6M | 106.49 | +551.3% |
| EVMN Evommune, Inc. | 80.3M | 0.9% | 3.5M | 14.02 | — |
| CLYM Climb Bio, Inc. | 77.4M | 0.8% | 11.3M | 17.28 | +668.0% |
| SLDB Solid Biosciences Inc. | 67.2M | 0.7% | 9.3M | 9.30 | +64.3% |
| ARTV Artiva Biotherapeutics, Inc. | 63.5M | 0.7% | 9.9M | 10.93 | +303.3% |
| DMRA Damora Therapeutics, Inc. | 62.1M | 0.7% | 2.4M | 30.82 | +811.9% |
| XNCR Xencor Inc | 59.1M | 0.6% | 4.9M | 27.80 | +270.2% |
| LBRX LB PHARMACEUTICALS INC | 54.5M | 0.6% | 2.2M | 47.62 | — |
| JBIO Jade Biosciences, Inc. | 51.6M | 0.5% | 3.7M | 21.34 | +211.5% |
| ABOS Acumen Pharmaceuticals, Inc. | 49.5M | 0.5% | 21.0M | 3.16 | +124.1% |
| FDMT 4D Molecular Therapeutics, Inc. | 47.0M | 0.5% | 5.0M | 15.83 | +131.1% |
| FULC Fulcrum Therapeutics, Inc. | 46.4M | 0.5% | 6.1M | 3.83 | -41.7% |
| CAPR CAPRICOR THERAPEUTICS, INC. | 45.8M | 0.5% | 1.5M | 6.29 | -12.3% |
| IPSC Century Therapeutics, Inc. | 40.1M | 0.4% | 17.8M | 2.07 | +279.8% |
| OLMA Olema Pharmaceuticals, Inc. | 38.8M | 0.4% | 2.6M | 10.69 | +96.1% |
| LENZ LENZ Therapeutics, Inc. | 38.2M | 0.4% | 4.2M | 4.68 | -87.9% |
| MNPR Monopar Therapeutics | 36.6M | 0.4% | 667.2K | 107.72 | +226.4% |
| PEPG PepGen Inc. | 35.5M | 0.4% | 20.1M | 3.14 | +155.3% |
| DSGN Design Therapeutics, Inc. | 31.6M | 0.3% | 3.0M | 14.99 | +212.9% |
| MIRM Mirum Pharmaceuticals, Inc. | 29.4M | 0.3% | 318.6K | 96.31 | +44.4% |
| BIOA BioAge Labs, Inc. | 28.9M | 0.3% | 1.7M | 9.48 | +113.5% |
| LXEO Lexeo Therapeutics, Inc. | 28.7M | 0.3% | 5.0M | 4.88 | +1.7% |
| ASMB ASSEMBLY BIOSCIENCES, INC. | 28.3M | 0.3% | 1.0M | 34.38 | +31.5% |
| RZLT Rezolute, Inc. | 28.0M | 0.3% | 9.2M | 5.09 | -23.6% |
| AKTS Aktis Oncology, Inc. | 26.9M | 0.3% | 1.5M | 24.07 | +19858.5% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →